Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial German regulatory agency, Paul-Ehrlic…
First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial German regulatory agency, Paul-Ehrlic…
. - Projekt wird gemeinsam von den Biotechnologiefirmen immatics (Tübingen) und BioNTech (Mainz) geleitet - Regulator…
. - Glioma Actively Personalized Vaccine Consortium (GAPVAC): 14 Institutionen aus Europa und den USA entwickeln einen…